Remarkably, a higher percentage of these critical and unique macrophages (as identified by the presence of the AM-specific surface marker CD11c and Siglec-F) were already found in the AnxA1-treated mice prior to infection, suggesting that the beneficial effect of administering AnxA1 was due to an expansion of this AM population. This evidence concerns the gene ITGAX and infection.